Covered recipient · General Payments record
MARC THOMAS ROTH
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$6,536.47
4 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $6,240.00 | 1 |
| Food and Beverage | $296.47 | 3 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $6,240.00 | 1 |
| Caris MPI, Inc. | $140.24 | 1 |
| HISTOSONICS, INC. | $139.18 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.05 | 1 |
Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MARC THOMAS ROTH
NPI 1619364213 · CMS profile ID 5699263
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
KANSAS CITY, MO
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1619364213?year=2025&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MARC THOMAS ROTH, NPI 1619364213, CMS profile ID 5699263. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619364213?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). MARC THOMAS ROTH, NPI 1619364213, CMS profile ID 5699263. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619364213?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- MARC THOMAS ROTH, NPI 1619364213, CMS profile ID 5699263, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1619364213?year=2025&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
4 matching records · $6,536.47 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–4 of 4.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $17.05 | 08/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223833207 | CMS |
| Caris MPI, Inc. | $140.24 | 05/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234285753 | CMS |
| HISTOSONICS, INC. | $139.18 | 01/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233992076 | CMS |
| E.R. Squibb & Sons, L.L.C. | $6,240.00 | 01/15/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184688617 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $244,846.16 | 51 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
51 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination with Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202420858 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 12/30/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202420844 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 12/30/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202420848 |
| Principal investigator 1 | ABBVIE INC. | $5,250.00 | 12/30/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202420852 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 12/30/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202420855 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 12/09/2025 | Covered Recipient Teaching Hospital Saint Lukes Hospital Of Kansas City | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211555041 |
| Principal investigator 1 | Genentech, Inc. | $2,200.00 | 12/09/2025 | Covered Recipient Teaching Hospital Saint Lukes Hospital Of Kansas City | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211555045 |
| Principal investigator 1 | Genentech, Inc. | $3,200.00 | 12/09/2025 | Covered Recipient Teaching Hospital Saint Lukes Hospital Of Kansas City | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211555049 |
| Principal investigator 1 | Genentech, Inc. | $9,270.00 | 12/01/2025 | Covered Recipient Teaching Hospital Saint Lukes Hospital Of Kansas City | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211555037 |
| Principal investigator 1 | Genentech, Inc. | $3,200.00 | 10/21/2025 | Covered Recipient Teaching Hospital Saint Lukes Hospital Of Kansas City | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211555010 |
| Principal investigator 1 | Genentech, Inc. | $3,150.00 | 10/21/2025 | Covered Recipient Teaching Hospital Saint Lukes Hospital Of Kansas City | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211555016 |
| Principal investigator 1 | Genentech, Inc. | $670.00 | 10/21/2025 | Covered Recipient Teaching Hospital Saint Lukes Hospital Of Kansas City | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211555021 |
| Principal investigator 1 | Genentech, Inc. | $1,750.00 | 10/21/2025 | Covered Recipient Teaching Hospital Saint Lukes Hospital Of Kansas City | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211555025 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 10/21/2025 | Covered Recipient Teaching Hospital Saint Lukes Hospital Of Kansas City | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211555028 |
| Principal investigator 1 | Genentech, Inc. | $3,200.00 | 10/07/2025 | Covered Recipient Teaching Hospital Saint Lukes Hospital Of Kansas City | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211555033 |
| Principal investigator 1 | ABBVIE INC. | $6,050.00 | 09/18/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (AndroMETa-CRC) | No dispute reported | 06/30/2026 | 1202420824 |
| Principal investigator 1 | ABBVIE INC. | $12,443.24 | 08/14/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202420821 |
| Principal investigator 1 | ABBVIE INC. | $104.52 | 08/04/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202420791 |
| Principal investigator 1 | ABBVIE INC. | $1,750.00 | 08/04/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202420796 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 08/04/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202420799 |
| Principal investigator 1 | ABBVIE INC. | $100.50 | 08/04/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202420802 |
| Principal investigator 1 | ABBVIE INC. | $2,000.00 | 08/04/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202420805 |
| Principal investigator 1 | ABBVIE INC. | $100.50 | 08/04/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202420810 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 08/04/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202420814 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 08/04/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202420817 |
| Principal investigator 1 | ABBVIE INC. | $5,500.00 | 08/01/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202420788 |
| Principal investigator 1 | Genentech, Inc. | $17,575.00 | 07/22/2025 | Covered Recipient Teaching Hospital Saint Lukes Hospital Of Kansas City | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211555003 |
| Principal investigator 1 | Genentech, Inc. | $50.00 | 07/22/2025 | Covered Recipient Teaching Hospital Saint Lukes Hospital Of Kansas City | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211555006 |
| Principal investigator 1 | ABBVIE INC. | $3,435.76 | 05/30/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202420781 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 05/16/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202420772 |
| Principal investigator 1 | ABBVIE INC. | $4,250.00 | 05/16/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202420776 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $37,219.08 | 05/09/2025 | Covered Recipient Teaching Hospital Saint Lukes Hospital Of Kansas City | a phase 3 multi center,open label,sponsor blinded,randomized study of azd0901 monotherapy compared with investigator s choice of therapy in second or later line adult participants with advanced metastatic gastric or gastroesophageal junction adenocarcinoma expressing claudin18 2 | No dispute reported | 06/30/2026 | 1185538897 |
| Principal investigator 1 | ABBVIE INC. | $21,700.00 | 05/07/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (AndroMETa-CRC) | No dispute reported | 06/30/2026 | 1202420768 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 04/30/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202420748 |
| Principal investigator 1 | ABBVIE INC. | $1,400.00 | 04/30/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202420751 |
| Principal investigator 1 | ABBVIE INC. | $8,250.00 | 04/30/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202420756 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 04/30/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202420760 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 04/30/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202420764 |
| Principal investigator 1 | ABBVIE INC. | $21,505.26 | 03/26/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | M18-868 - A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202420744 |
| Principal investigator 1 | Genentech, Inc. | $2,200.00 | 03/20/2025 | Covered Recipient Teaching Hospital Saint Lukes Hospital Of Kansas City | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211554978 |
| Principal investigator 1 | ABBVIE INC. | $3,536.26 | 03/18/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | M18-868 - A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202420735 |
| Principal investigator 1 | ABBVIE INC. | $8,986.04 | 03/18/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | M18-868 - A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202420740 |
| Principal investigator 1 | ABBVIE INC. | $75.00 | 03/07/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | M18-868 - A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202420731 |
| Principal investigator 1 | ABBVIE INC. | $4,850.00 | 02/13/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | M18-868 - A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202420724 |
| Principal investigator 1 | ABBVIE INC. | $75.00 | 02/06/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | M18-868 - A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202420715 |
| Principal investigator 1 | Genentech, Inc. | $18,200.00 | 01/14/2025 | Covered Recipient Teaching Hospital Saint Lukes Hospital Of Kansas City | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211554981 |
| Principal investigator 1 | Genentech, Inc. | $5,000.00 | 01/14/2025 | Covered Recipient Teaching Hospital Saint Lukes Hospital Of Kansas City | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211554986 |
| Principal investigator 1 | Genentech, Inc. | $800.00 | 01/14/2025 | Covered Recipient Teaching Hospital Saint Lukes Hospital Of Kansas City | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211554990 |
| Principal investigator 1 | Genentech, Inc. | $3,500.00 | 01/14/2025 | Covered Recipient Teaching Hospital Saint Lukes Hospital Of Kansas City | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211554995 |
| Principal investigator 1 | Genentech, Inc. | $12,800.00 | 01/07/2025 | Covered Recipient Teaching Hospital Saint Lukes Hospital Of Kansas City | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211554998 |
| Principal investigator 1 | ABBVIE INC. | $150.00 | 01/02/2025 | Covered Recipient Teaching Hospital SAINT LUKES HOSPITAL OF KANSAS CITY | M18-868 - A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202420706 |